BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM

Company CEO and CBO will be available throughout BIO 2022 for partnering meetings

BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that Kristen Fortney, PhD, CEO and Co-Founder of BioAge, will lead a panel discussion at the BIO International Conference held June 13–16, 2022 in San Diego, California (“BIO 2022”).

Event details are as follows:

“Aging is the primary driver of many serious diseases. Together with other leading companies in this new and exciting space, we will discuss the challenge and promise of developing drugs that address this enormous unmet clinical need,” said Dr. Fortney. “Our BIO 2022 panel will be a fantastic event of deep interest to pharma, investors, founders, and researchers in the emerging field of longevity-based therapeutics.”

Opportunities for partnership with BioAge

Dr. Fortney and Peng Leong, PhD, MBA, BioAge’s chief business officer (CBO) and Head of Brain Aging, will be available throughout the conference to meet to discuss partnerships and opportunities with interested parties. Attendees can send meeting requests to BioAge via the BIO 2022 partnering system [link] or via the contact information in this release.

“BioAge’s discovery platform, based on analysis of human longevity data, has already yielded multiple clinical assets including our apelin receptor agonist for treatment of muscle aging, as well as novel advanced lead compounds such as our recently announced novel family of NLRP3 inhibitors,” said Dr. Leong. “The platform will continue to reveal promising new targets and therapies to treat diseases of aging, and we look forward to meeting potential partners, collaborators, and investors face to face at this extraordinary conference.”

BIO 2022 is organized by the Biotechnology Innovation Organization (BIO), the world’s largest advocacy association for the biotech industry. The mission of BIO 2022 is to promote global partnerships, collaboration, and thought leadership in biotechnology. Registration for the conference is open. [link]

About BioAge Labs, Inc.

BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records to map the key molecular pathways that impact healthy human aging. By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or prevent age-related disease in entirely new ways. BioAge has multiple clinical programs in its growing portfolio targeting muscle, immune, and brain aging, including BGE-105 (Phase 1: muscle atrophy), BGE-175 (Phase 2: COVID-19, influenza, and beyond), and BGE-117 (Phase 2: muscle aging), as well as proprietary NLRP3 inhibitors (preclinical development, inflammatory and age-related neurological diseases). To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005298/en/